ATG9A and ovarian serous cystadenocarcinoma: To confirm ATG9A’s clinical relevance, we analyzed TCGA data20 and found that lower ATG9A mRNA levels correlate with improved overall survival in ovarian serous cystadenocarcinoma (Supplementary Fig. 3A).